Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) - NBC Right Now/KNDO/KNDU Tri-Cities, Yakima, WA |

Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT)

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Decision Resources Group

However, New Agents Seeking To Penetrate the OPAT Market Must Gain Favorable Positioning in the Hospital Setting, According to Findings from Decision Resources Group

BURLINGTON, Mass., July 10, 2014 /PRNewswire/ -- Decision Resources Group finds that while more than three-quarters of surveyed infectious disease (ID) specialists are willing to prescribe Durata's Dalvance (dalbavancin) and The Medicines Company's Orbactiv (oritavancin) for use as OPAT, approximately two-thirds of the respondents reported a willingness to prescribe these agents to their hospital inpatients. However, our findings indicate that nearly two-thirds (64 percent) of OPAT patients are initiated on OPAT following hospital discharge, and most are discharged on OPAT on the same antibiotic they received as inpatients. These findings suggest that new antibiotics looking to gain traction in the OPAT market must gain inclusion on hospital formularies and position themselves as preferred agents in the hospital setting.

Decision Resources Group Logo.

Other key findings from the 2014 U.S. TreatmentTrends report entitled Hospital Discharge and Outpatient Parenteral Antimicrobial Therapy (OPAT):

  • ID specialists as key stakeholders in OPAT market: ID specialists are the healthcare providers most frequently involved in identifying a patient for discharge on OPAT; nearly three-quarters (72 percent) of surveyed ID specialists indicated that their hospital requires prior consultation with an ID specialist to evaluate and setup patients for OPAT.
  • Observation rooms/interim facilities for reducing hospital admissions: More than three quarters (82 percent) of surveyed ID specialists indicated that their hospital has facilities for keeping patients requiring short-term monitoring (less than 48 hours) without admitting them to the hospital. Over half of these facilities are used to administer IV antibiotics and can play an important role in decisions about whether to admit patients or discharge them on outpatient therapy.
  • Preference for oral antibiotics over OPAT: Oral therapies offer the potential to substantially simplify antibiotic treatment compared with therapies that are administered intravenously. Not surprisingly, surveyed ID specialists reported being more likely to prescribe oral formulations of both Cubist's Sivextro (tedizolid) and Tetraphase's emerging drug eravacycline when discharging patients than OPAT with either drug, suggesting oral formulations of these agents will see greater use as discharge therapy.

Comments from Decision Resources Group Analyst Hannah E. Cummings, Ph.D.:

  • "Hospitals are actively looking to cut costs and reduce or shorten admissions, and discharging patients on OPAT is an important part of their strategy. OPAT is a particularly attractive treatment modality for patients presenting to the emergency room with an infection requiring IV antibiotic therapy but not necessitating admission. ID specialists and emergency room physicians are frequently involved in identifying and recommending patients for OPAT and will likely be key stakeholders in driving uptake of new OPAT therapies."
  • "Surveyed ID specialists identified a need for new OPAT drugs for infections due to drug-resistant pathogens that are dosed once daily. Although the OPAT market is highly genericized, agents demonstrating benefits in efficacy, dosing-frequency and/or administration, such as Cubist's Cubicin (daptomycin) and Merck's Invanz (ertapenem), have experienced widespread use in the OPAT market. New agents will also have to demonstrate improvements on these key attributes to successfully compete in the OPAT market segment."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597 
ccomfort@dresourcesgroup.com 

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KHQ. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.